To investigate the effects of myeloid cell-targeted ACSL1-deficiency in vivo, we injected ACSL1M−/− mice and WT littermate controls i.p. with pristane, used to model the IFN-I signature in SLE (51). This evidence concerns the gene ACSL1 and systemic lupus erythematosus.